<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00928083</url>
  </required_header>
  <id_info>
    <org_study_id>MMV_OZ439_09_001</org_study_id>
    <nct_id>NCT00928083</nct_id>
  </id_info>
  <brief_title>A Study to Investigate the Safety, Tolerability and Pharmacokinetics of OZ439 in Healthy Male and Female Subjects</brief_title>
  <official_title>A Phase I Study To Investigate The Safety, Tolerability And Pharmacokinetic Profile Of OZ439 In Healthy Male and Female Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medicines for Malaria Venture</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medicines for Malaria Venture</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      OZ439 is a synthetic trioxolane that has potential value as a peroxide antimalarial agent.

      This was a Phase I, single-centre, multi-component, double-blind, randomised,
      placebo-controlled study in healthy male and female subjects. The study was conducted in 3
      parts:

        -  Part A investigated the safety, tolerability and pharmacokinetics (PK) of single oral
           escalating doses of OZ439. Up to 6 dose levels will be investigated to estimate dose
           proportionality.

        -  Part B, the effect of food on a single oral dose of OZ439 was investigated in a 2-way
           crossover design.

        -  Part C investigated the safety, tolerability and PK profile of multiple oral doses of
           OZ439.

      The starting oral dose was 50 mg and the maximum single dose to be administered did not
      exceed 1600 mg per subject. The maximum duration of dosing proposed was 3 days.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>From screening and at 10 (+/-2) days after last dose of study medication</time_frame>
    <description>Safety/Tolerability evaluation took into account the recorded AE profile, clinical laboratory safety tests, vital signs, 12 lead and continuous (Parts A and C) ECG monitoring, audiometry/Brainstem Auditory Evoked Potentials (BAEP) parameters (Parts A and C) including any additional tests required to evaluate any safety concerns.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>OZ439 AUC0-t</measure>
    <time_frame>Samples collected from Pre-dose up to 96h post dose</time_frame>
    <description>Area under the plasma concentration-time curve from zero to time t of the last measured concentration above the limit of quantification (AUC0-t).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OZ439 AUC0-∝</measure>
    <time_frame>Samples collected from Pre-dose up to 96h post dose</time_frame>
    <description>Area under the plasma concentration-time curve from zero to infinity (AUC0-∝).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OZ439 Cmax</measure>
    <time_frame>Samples collected from Pre-dose up to 96h post dose</time_frame>
    <description>Maximum observed plasma drug concentration (Cmax).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OZ439 Tmax</measure>
    <time_frame>Samples collected from Pre-dose up to 96h post dose</time_frame>
    <description>Time to maximum observed plasma drug concentration of OZ439</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OZ439 t1/2</measure>
    <time_frame>Samples collected from Pre-dose up to 96h post dose</time_frame>
    <description>Apparent terminal half-life (t1/2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OZ439 Rac</measure>
    <time_frame>Samples collected from Pre-dose up to 96h post dose</time_frame>
    <description>Accumulation index is the ratio of drug exposure observed during a dosing interval at steady-state divided by drug exposure after a single first dose, as described by the following equations:
Accumulation index (Rac) = AUC0-(Day 3)/ AUC0-(Day 1)</description>
  </secondary_outcome>
  <number_of_arms>17</number_of_arms>
  <enrollment type="Actual">63</enrollment>
  <condition>Malaria Falciparum</condition>
  <condition>Malaria Vivax</condition>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Part A - 50 mg Single Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OZ439 Single doses of 50mg (capsules)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A - 100mg Single Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OZ439 Single doses of 100mg (capsules)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A - 200mg Single Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OZ439 Single doses of 200mg (capsules)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A - 400mg Single Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OZ439 Single doses of 400mg (capsules)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A - 400mg Single Dose + Food</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OZ439 Single doses of 400mg (capsules) administered with food.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A - 400mg AD Single Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OZ439 Single doses of 400mg (aqueous dispersion)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A - 800mg Single Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OZ439 Single doses of 800mg (capsules)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A - 800mg AD Single Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OZ439 Single doses of 800mg (aqueous dispersion)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A - 1200mg Single Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OZ439 Single doses of 1200mg (capsules)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A - 1600mg AD Single Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OZ439 Single doses of 800mg (aqueous dispersion)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A - Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo control for Single rising Part A</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B - 800mg AD Single Dose Fed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of OZ439 800mg aqueous dispersion administered under fed conditions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B - 800mg AD Single Dose Fast</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of OZ439 800mg aqueous dispersion administered under fast conditions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part C - 200mg AD Multiple Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>200mg aqueous solution OZ439 or placebo once daily for 3 days fasted</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part C - 400mg AD Multiple Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>400mg aqueous solution OZ439 or placebo once daily for 3 days fasted</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part C - 800mg AD Multiple Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>800mg aqueous solution OZ439 or placebo once daily for 3 days fasted</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part C - Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo control for Multiple rising Part C</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OZ439 50mg API capsules</intervention_name>
    <arm_group_label>Part A - 50 mg Single Dose</arm_group_label>
    <other_name>OZ439</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OZ439 200mg API capsules</intervention_name>
    <arm_group_label>Part A - 200mg Single Dose</arm_group_label>
    <other_name>OZ439</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OZ439 400mg aqueous dispersion</intervention_name>
    <arm_group_label>Part A - 400mg AD Single Dose</arm_group_label>
    <arm_group_label>Part C - 400mg AD Multiple Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OZ439 800mg aqueous dispersion</intervention_name>
    <arm_group_label>Part A - 800mg AD Single Dose</arm_group_label>
    <arm_group_label>Part B - 800mg AD Single Dose Fed</arm_group_label>
    <arm_group_label>Part B - 800mg AD Single Dose Fast</arm_group_label>
    <arm_group_label>Part C - 800mg AD Multiple Dose</arm_group_label>
    <other_name>OZ439</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OZ439 100mg API capsules</intervention_name>
    <description>OZ439 100mg (2x50mg API capsules)</description>
    <arm_group_label>Part A - 100mg Single Dose</arm_group_label>
    <other_name>OZ439</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OZ439 400mg API capsules</intervention_name>
    <description>OZ439 400mg (2x200mg API capsules)</description>
    <arm_group_label>Part A - 400mg Single Dose</arm_group_label>
    <arm_group_label>Part A - 400mg Single Dose + Food</arm_group_label>
    <other_name>OZ439</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OZ439 1600mg aqueous dispersion</intervention_name>
    <arm_group_label>Part A - 1600mg AD Single Dose</arm_group_label>
    <other_name>OZ439</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OZ439 800mg API capsules</intervention_name>
    <description>OZ439 800mg (4x200 API capsules)</description>
    <arm_group_label>Part A - 800mg Single Dose</arm_group_label>
    <other_name>OZ439</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OZ439 1200mg API capsules</intervention_name>
    <description>OZ439 1200mg (6x200mg API capsules)</description>
    <arm_group_label>Part A - 1200mg Single Dose</arm_group_label>
    <other_name>OZ439</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Part A - Placebo</arm_group_label>
    <arm_group_label>Part C - Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OZ439 200mg aqueous dispersion</intervention_name>
    <arm_group_label>Part C - 200mg AD Multiple Dose</arm_group_label>
    <other_name>OZ439</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy male//female subjects between 18- 55 years of age (inclusive).

          2. Body mass Index (BMI) between 18 - 30 kg/m2, inclusive; and a total body weight &gt;60 kg
             (132 lbs).

          3. Healthy as determined by pre-study medical history, PE, 12 Lead ECG.

          4. Females of childbearing potential must use 1 of birth control methods throughout study
             and for 30 days after last dose of study drug:

               1. Surgically sterile (bilateral tubal ligation, hysterectomy, bilateral
                  oophorectomy) 6 months minimum prior to first dose of study drug.

               2. Intrauterine device (IUD) in place for at least 3 months prior to first dose of
                  study drug.

               3. Barrier methods (condom or diaphragm) with spermicide starting at least 14 days
                  prior to first dose of study drug through 30 days after last dose of study drug.

               4. Surgical sterilization of the partner(s) (vasectomy with zero sperm count for 6
                  months minimum prior to the first dose of study drug).

               5. Hormonal contraceptives starting at least 3 months prior to first dose of study
                  drug. In addition, subjects must agree to use a barrier method (condom or
                  diaphragm) with spermicide at least 14 days prior to first dose of study drug
                  through 30 days after the last dose of study drug.

          5. Post-menopausal women with amenorrhea for at least 1 year will be eligible confirmed
             by FSH.

          6. Male subjects must agree to use double barrier method of contraception, from time of
             first dose of study drug through 90 days after last dose of study drug and must also
             agree to not donate sperm for 90 days after last dose of study drug. Clinical
             laboratory tests within the reference ranges.

          7. Able/willing to give written informed consent.

          8. Willing/to adhere to lifestyle guideline restrictions outlined in protocol.

          9. Willing and able to be confined to Clinical Research Unit as required by the protocol.

        Exclusion Criteria:

          1. Evidence/history of clinically significant oncologic, pulmonary, hepatic,
             cardiovascular, hematologic, metabolic, neurological, immunologic, nephrologic,
             endocrine, psychiatric disease, current infection.

          2. Evidence/history of clinically significant gastrointestinal (some exclusions exist)
             disease, current infection.

          3. Any condition that affecting drug absorption, e.g., gastrectomy.

          4. History of post-antibiotic colitis.

          5. Breast feeding.

          6. QTc greater than 450 msec for males and 470 msec for females as corrected by the
             Bazett formula.

          7. History of drug or alcohol abuse within the past 2 years prior to Screening.

          8. Tobacco users

          9. Received investigational drug/ participated in another research study within 30 days
             of first dose of study drug in any part of study.

         10. Use of prescription drugs within 14 days prior to the first dose of study drug in
             Period 1, or need for any antibiotic during study.

         11. Received any non prescription meds, vitamins, herbal/dietary supplements within 7 days
             of administration of first dose of study drug in Period 1 (exceptions exist)

         12. Consumed alcohol within 72 hours of Day -1 in any part of study, or have a positive
             alcohol screen at screening or each admission to Clinical Research Unit (CRU).

         13. Consumed grapefruit juice or juices containing grapefruit or ate grapefruit within 7
             days prior to first dose of study drug in any part of study.

         14. Positive serum pregnancy test at the Screening Visit or on Day -1 prior to inclusion
             in any part of the study.

         15. Positive test for HIV-1, HBsAg,HCV.

         16. Positive urine drug screen at Screening or admission to CRU.

         17. History of intolerance/ hypersensitivity to artemisinins.

         18. Likelihood of requiring treatment during study period with drugs not permitted by
             protocol.

         19. Subjects who have donated blood or experienced significant blood loss within 60 days
             of screening for study.

         20. Subjects whose hemoglobin is &lt;12.5 g/dL for males/ &lt;11.5 g/dL for females.

         21. Any concern by investigator regarding safe participation of the subject in study or
             for any other reason investigator considers subject inappropriate for participation in
             study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joerg Moehrle, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Medicines for Malaria Venture</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Maria Gutierrez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Comprehensive Phase One Miramar, 3400 Enterprise Way, Miramar, FL 33025</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Comprehensive Phase One Miramar; 3400 Enterprise Way</name>
      <address>
        <city>Miramar</city>
        <state>Florida</state>
        <zip>33025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mmv.org</url>
    <description>Medicines for Malaria Venture</description>
  </link>
  <results_reference>
    <citation>Moehrle JJ, Duparc S, Siethoff C, van Giersbergen PL, Craft JC, Arbe-Barnes S, Charman SA, Gutierrez M, Wittlin S, Vennerstrom JL. First-in-man safety and pharmacokinetics of synthetic ozonide OZ439 demonstrates an improved exposure profile relative to other peroxide antimalarials. Br J Clin Pharmacol. 2013 Feb;75(2):524-37. doi: 10.1111/j.1365-2125.2012.04368.x.</citation>
    <PMID>22759078</PMID>
  </results_reference>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 24, 2009</study_first_submitted>
  <study_first_submitted_qc>June 24, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 25, 2009</study_first_posted>
  <results_first_submitted>November 10, 2014</results_first_submitted>
  <results_first_submitted_qc>January 7, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 8, 2015</results_first_posted>
  <last_update_submitted>January 7, 2015</last_update_submitted>
  <last_update_submitted_qc>January 7, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 8, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase I</keyword>
  <keyword>Safety and tolerability</keyword>
  <keyword>Pharmacokinetic</keyword>
  <keyword>synthetic peroxide</keyword>
  <keyword>trioxolane</keyword>
  <keyword>treatment of erythrocytic stages of malaria</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
    <mesh_term>Malaria, Falciparum</mesh_term>
    <mesh_term>Malaria, Vivax</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Part A - OZ439 Single Dose - Cohort 1</title>
          <description>OZ439 50 mg then 200 mg, then 800 mg, then 1600 mg, then Placebo</description>
        </group>
        <group group_id="P2">
          <title>Part A - OZ439 Single Dose - Cohort 2</title>
          <description>OZ439 50 mg, then 100 mg, then 400 mg, then 1200 mg, then Placebo</description>
        </group>
        <group group_id="P3">
          <title>Part A - OZ439 Single Dose - Cohort 3</title>
          <description>Oral Dispersion OZ439 50-1600 mg</description>
        </group>
        <group group_id="P4">
          <title>Part B - Food Effect - Cohort 1</title>
          <description>Food Effect - Cohort 1 800mg OZ439 Fasted then Fed</description>
        </group>
        <group group_id="P5">
          <title>Part B - Food Effect - Cohort 2</title>
          <description>Food Effect - Cohort 2 800mg OZ439 Fed then Fasted</description>
        </group>
        <group group_id="P6">
          <title>Part C - 200mg OZ439 Multiple Dose</title>
          <description>200mg OZ439 for 3 consecutive days</description>
        </group>
        <group group_id="P7">
          <title>Part C - 400mg OZ439 Multiple Dose</title>
          <description>OZ439 400mg for 3 consecutive days</description>
        </group>
        <group group_id="P8">
          <title>Part C - 800mg OZ439 Multiple Dose</title>
          <description>OZ439 800mg for 3 consecutive days</description>
        </group>
        <group group_id="P9">
          <title>Part C - Placebo</title>
          <description>Part C - Placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="6"/>
                <participants group_id="P9" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="6"/>
                <participants group_id="P9" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Part A - OZ439 Single Rising Dose</title>
          <description>Included 3 Cohorts, where subjects in cohorts 1 and 2 were randomized to a treatment sequence, receiving doses of OZ439 on four occasions and placebo on one occasion, and subjects in Cohort 3 were administered increasing doses of the oral dispersion.</description>
        </group>
        <group group_id="B2">
          <title>Part B - OZ439 Food Effect</title>
          <description>Subjects were randomized to sequence groups, &quot;fasted/fed or fed/fasted&quot; while receiving a single dose of 800 mg OZ439.</description>
        </group>
        <group group_id="B3">
          <title>Part C - OZ439 Multiple Rising Dose</title>
          <description>Subjects were assigned to individual dose cohorts (200, 400 and 800 mg OZ439) and placebo.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="26"/>
            <count group_id="B2" value="13"/>
            <count group_id="B3" value="24"/>
            <count group_id="B4" value="63"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.6" spread="10.35"/>
                    <measurement group_id="B2" value="33.7" spread="8.49"/>
                    <measurement group_id="B3" value="40.1" spread="10.17"/>
                    <measurement group_id="B4" value="36.5" spread="9.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Adverse Events</title>
        <description>Safety/Tolerability evaluation took into account the recorded AE profile, clinical laboratory safety tests, vital signs, 12 lead and continuous (Parts A and C) ECG monitoring, audiometry/Brainstem Auditory Evoked Potentials (BAEP) parameters (Parts A and C) including any additional tests required to evaluate any safety concerns.</description>
        <time_frame>From screening and at 10 (+/-2) days after last dose of study medication</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Part A - 50 mg Single Dose</title>
            <description>OZ439 Single doses of 50mg (capsules)
OZ439 50mg API capsules</description>
          </group>
          <group group_id="O2">
            <title>Part A - 100mg Single Dose</title>
            <description>OZ439 Single doses of 100mg (capsules)
OZ439 100mg API capsules: OZ439 100mg (2x50mg API capsules)</description>
          </group>
          <group group_id="O3">
            <title>Part A - 200mg Single Dose</title>
            <description>OZ439 Single doses of 200mg (capsules)
OZ439 200mg API capsules</description>
          </group>
          <group group_id="O4">
            <title>Part A - 400mg Single Dose</title>
            <description>OZ439 Single doses of 400mg (capsules)
OZ439 400mg API capsules: OZ439 400mg (2x200mg API capsules)</description>
          </group>
          <group group_id="O5">
            <title>Part A - 400mg Single Dose + Food</title>
            <description>OZ439 Single doses of 400mg (capsules) administered with food.
OZ439 400mg API capsules: OZ439 400mg (2x200mg API capsules)</description>
          </group>
          <group group_id="O6">
            <title>Part A - 400mg AD Single Dose</title>
            <description>OZ439 Single doses of 400mg (aqueous dispersion)
OZ439 400mg aqueous dispersion</description>
          </group>
          <group group_id="O7">
            <title>Part A - 800mg Single Dose</title>
            <description>OZ439 Single doses of 800mg (capsules)
OZ439 800mg API capsules: OZ439 800mg (4x200 API capsules)</description>
          </group>
          <group group_id="O8">
            <title>Part A - 800mg AD Single Dose</title>
            <description>OZ439 Single doses of 800mg (aqueous dispersion)
OZ439 800mg aqueous dispersion</description>
          </group>
          <group group_id="O9">
            <title>Part A - 1200mg Single Dose</title>
            <description>OZ439 Single doses of 1200mg (capsules)
OZ439 1200mg API capsules: OZ439 1200mg (6x200mg API capsules)</description>
          </group>
          <group group_id="O10">
            <title>Part A - 1600mg AD Single Dose</title>
            <description>OZ439 Single doses of 800mg (aqueous dispersion)
OZ439 1600mg aqueous dispersion</description>
          </group>
          <group group_id="O11">
            <title>Part A - Placebo</title>
            <description>Placebo control for Single rising Part A
Placebo</description>
          </group>
          <group group_id="O12">
            <title>Part B - 800mg AD Single Dose Fed</title>
            <description>Single dose of OZ439 800mg aqueous dispersion administered under fed conditions
OZ439 800mg aqueous dispersion</description>
          </group>
          <group group_id="O13">
            <title>Part B - 800mg AD Single Dose Fast</title>
            <description>Single dose of OZ439 800mg aqueous dispersion administered under fast conditions
OZ439 800mg aqueous dispersion</description>
          </group>
          <group group_id="O14">
            <title>Part C - 200mg AD Multiple Dose</title>
            <description>200mg aqueous solution OZ439 or placebo once daily for 3 days fasted
OZ439 200mg aqueous dispersion</description>
          </group>
          <group group_id="O15">
            <title>Part C - 400mg AD Multiple Dose</title>
            <description>400mg aqueous solution OZ439 or placebo once daily for 3 days fasted
OZ439 400mg aqueous dispersion</description>
          </group>
          <group group_id="O16">
            <title>Part C - 800mg AD Multiple Dose</title>
            <description>800mg aqueous solution OZ439 or placebo once daily for 3 days fasted
OZ439 800mg aqueous dispersion</description>
          </group>
          <group group_id="O17">
            <title>Part C - Placebo</title>
            <description>Placebo control for Multiple rising Part C
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Events</title>
          <description>Safety/Tolerability evaluation took into account the recorded AE profile, clinical laboratory safety tests, vital signs, 12 lead and continuous (Parts A and C) ECG monitoring, audiometry/Brainstem Auditory Evoked Potentials (BAEP) parameters (Parts A and C) including any additional tests required to evaluate any safety concerns.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="6"/>
                <count group_id="O11" value="17"/>
                <count group_id="O12" value="12"/>
                <count group_id="O13" value="12"/>
                <count group_id="O14" value="6"/>
                <count group_id="O15" value="6"/>
                <count group_id="O16" value="6"/>
                <count group_id="O17" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="5"/>
                    <measurement group_id="O11" value="4"/>
                    <measurement group_id="O12" value="3"/>
                    <measurement group_id="O13" value="4"/>
                    <measurement group_id="O14" value="3"/>
                    <measurement group_id="O15" value="1"/>
                    <measurement group_id="O16" value="4"/>
                    <measurement group_id="O17" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>OZ439 AUC0-t</title>
        <description>Area under the plasma concentration-time curve from zero to time t of the last measured concentration above the limit of quantification (AUC0-t).</description>
        <time_frame>Samples collected from Pre-dose up to 96h post dose</time_frame>
        <population>Pharmacokinetics Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part A - 50 mg Single Dose</title>
            <description>OZ439 Single doses of 50mg (capsules)
OZ439 50mg API capsules</description>
          </group>
          <group group_id="O2">
            <title>Part A - 100mg Single Dose</title>
            <description>OZ439 Single doses of 100mg (capsules)
OZ439 100mg API capsules: OZ439 100mg (2x50mg API capsules)</description>
          </group>
          <group group_id="O3">
            <title>Part A - 200mg Single Dose</title>
            <description>OZ439 Single doses of 200mg (capsules)
OZ439 200mg API capsules</description>
          </group>
          <group group_id="O4">
            <title>Part A - 400mg Single Dose</title>
            <description>OZ439 Single doses of 400mg (capsules)
OZ439 400mg API capsules: OZ439 400mg (2x200mg API capsules)</description>
          </group>
          <group group_id="O5">
            <title>Part A - 400mg AD Single Dose</title>
            <description>OZ439 Single doses of 400mg (aqueous dispersion)
OZ439 400mg aqueous dispersion</description>
          </group>
          <group group_id="O6">
            <title>Part A - 800mg Single Dose</title>
            <description>OZ439 Single doses of 800mg (capsules)
OZ439 800mg API capsules: OZ439 800mg (4x200 API capsules)</description>
          </group>
          <group group_id="O7">
            <title>Part A - 800mg AD Single Dose</title>
            <description>OZ439 Single doses of 800mg (aqueous dispersion)
OZ439 800mg aqueous dispersion</description>
          </group>
          <group group_id="O8">
            <title>Part A - 1200mg Single Dose</title>
            <description>OZ439 Single doses of 1200mg (capsules)
OZ439 1200mg API capsules: OZ439 1200mg (6x200mg API capsules)</description>
          </group>
          <group group_id="O9">
            <title>Part A - 1600mg AD Single Dose</title>
            <description>OZ439 Single doses of 800mg (aqueous dispersion)
OZ439 1600mg aqueous dispersion</description>
          </group>
          <group group_id="O10">
            <title>Part B - 800mg AD Single Dose Fed</title>
            <description>Single dose of OZ439 800mg aqueous dispersion administered under fed conditions
OZ439 800mg aqueous dispersion</description>
          </group>
          <group group_id="O11">
            <title>Part B - 800mg AD Single Dose Fast</title>
            <description>Single dose of OZ439 800mg aqueous dispersion administered under fast conditions
OZ439 800mg aqueous dispersion</description>
          </group>
          <group group_id="O12">
            <title>Part C - 200mg AD Multiple Dose</title>
            <description>200mg aqueous solution OZ439 or placebo once daily for 3 days fasted
OZ439 200mg aqueous dispersion</description>
          </group>
          <group group_id="O13">
            <title>Part C - 400mg AD Multiple Dose</title>
            <description>400mg aqueous solution OZ439 or placebo once daily for 3 days fasted
OZ439 400mg aqueous dispersion</description>
          </group>
          <group group_id="O14">
            <title>Part C - 800mg AD Multiple Dose</title>
            <description>800mg aqueous solution OZ439 or placebo once daily for 3 days fasted
OZ439 800mg aqueous dispersion</description>
          </group>
        </group_list>
        <measure>
          <title>OZ439 AUC0-t</title>
          <description>Area under the plasma concentration-time curve from zero to time t of the last measured concentration above the limit of quantification (AUC0-t).</description>
          <population>Pharmacokinetics Population</population>
          <units>ng.h/ml</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="12"/>
                <count group_id="O11" value="12"/>
                <count group_id="O12" value="6"/>
                <count group_id="O13" value="6"/>
                <count group_id="O14" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="102" spread="133.7"/>
                    <measurement group_id="O2" value="249" spread="145.4"/>
                    <measurement group_id="O3" value="890" spread="89.1"/>
                    <measurement group_id="O4" value="1130" spread="186.6"/>
                    <measurement group_id="O5" value="5430" spread="72"/>
                    <measurement group_id="O6" value="3010" spread="115.7"/>
                    <measurement group_id="O7" value="9630" spread="56.9"/>
                    <measurement group_id="O8" value="6530" spread="172.4"/>
                    <measurement group_id="O9" value="17500" spread="70.1"/>
                    <measurement group_id="O10" value="23100" spread="48.9"/>
                    <measurement group_id="O11" value="7590" spread="64.7"/>
                    <measurement group_id="O12" value="3060" spread="60.1"/>
                    <measurement group_id="O13" value="7990" spread="57.5"/>
                    <measurement group_id="O14" value="13700" spread="46.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>OZ439 AUC0-∝</title>
        <description>Area under the plasma concentration-time curve from zero to infinity (AUC0-∝).</description>
        <time_frame>Samples collected from Pre-dose up to 96h post dose</time_frame>
        <population>Pharmacokinetics Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part A - 50 mg Single Dose</title>
            <description>OZ439 Single doses of 50mg (capsules)
OZ439 50mg API capsules</description>
          </group>
          <group group_id="O2">
            <title>Part A - 100mg Single Dose</title>
            <description>OZ439 Single doses of 100mg (capsules)
OZ439 100mg API capsules: OZ439 100mg (2x50mg API capsules)</description>
          </group>
          <group group_id="O3">
            <title>Part A - 200mg Single Dose</title>
            <description>OZ439 Single doses of 200mg (capsules)
OZ439 200mg API capsules</description>
          </group>
          <group group_id="O4">
            <title>Part A - 400mg Single Dose</title>
            <description>OZ439 Single doses of 400mg (capsules)
OZ439 400mg API capsules: OZ439 400mg (2x200mg API capsules)</description>
          </group>
          <group group_id="O5">
            <title>Part A - 400mg AD Single Dose</title>
            <description>OZ439 Single doses of 400mg (aqueous dispersion)
OZ439 400mg aqueous dispersion</description>
          </group>
          <group group_id="O6">
            <title>Part A - 800mg Single Dose</title>
            <description>OZ439 Single doses of 800mg (capsules)
OZ439 800mg API capsules: OZ439 800mg (4x200 API capsules)</description>
          </group>
          <group group_id="O7">
            <title>Part A - 800mg AD Single Dose</title>
            <description>OZ439 Single doses of 800mg (aqueous dispersion)
OZ439 800mg aqueous dispersion</description>
          </group>
          <group group_id="O8">
            <title>Part A - 1200mg Single Dose</title>
            <description>OZ439 Single doses of 1200mg (capsules)
OZ439 1200mg API capsules: OZ439 1200mg (6x200mg API capsules)</description>
          </group>
          <group group_id="O9">
            <title>Part A - 1600mg AD Single Dose</title>
            <description>OZ439 Single doses of 800mg (aqueous dispersion)
OZ439 1600mg aqueous dispersion</description>
          </group>
          <group group_id="O10">
            <title>Part B - 800mg AD Single Dose Fed</title>
            <description>Single dose of OZ439 800mg aqueous dispersion administered under fed conditions
OZ439 800mg aqueous dispersion</description>
          </group>
          <group group_id="O11">
            <title>Part B - 800mg AD Single Dose Fast</title>
            <description>Single dose of OZ439 800mg aqueous dispersion administered under fast conditions
OZ439 800mg aqueous dispersion</description>
          </group>
          <group group_id="O12">
            <title>Part C - 200mg AD Multiple Dose</title>
            <description>200mg aqueous solution OZ439 or placebo once daily for 3 days fasted
OZ439 200mg aqueous dispersion</description>
          </group>
          <group group_id="O13">
            <title>Part C - 400mg AD Multiple Dose</title>
            <description>400mg aqueous solution OZ439 or placebo once daily for 3 days fasted
OZ439 400mg aqueous dispersion</description>
          </group>
          <group group_id="O14">
            <title>Part C - 800mg AD Multiple Dose</title>
            <description>800mg aqueous solution OZ439 or placebo once daily for 3 days fasted
OZ439 800mg aqueous dispersion</description>
          </group>
        </group_list>
        <measure>
          <title>OZ439 AUC0-∝</title>
          <description>Area under the plasma concentration-time curve from zero to infinity (AUC0-∝).</description>
          <population>Pharmacokinetics Population</population>
          <units>ng.h/ml</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="12"/>
                <count group_id="O11" value="12"/>
                <count group_id="O12" value="6"/>
                <count group_id="O13" value="6"/>
                <count group_id="O14" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Insufficient data points for calculation</measurement>
                    <measurement group_id="O2" value="NA">Insufficient data points for calculation</measurement>
                    <measurement group_id="O3" value="NA">Insufficient data points for calculation</measurement>
                    <measurement group_id="O4" value="NA">Insufficient data points for calculation</measurement>
                    <measurement group_id="O5" value="5540" spread="71.3"/>
                    <measurement group_id="O6" value="4690" spread="43.5"/>
                    <measurement group_id="O7" value="9790" spread="56.7"/>
                    <measurement group_id="O8" value="9130" spread="136.8"/>
                    <measurement group_id="O9" value="18400" spread="68"/>
                    <measurement group_id="O10" value="23900" spread="49"/>
                    <measurement group_id="O11" value="8080" spread="68.7"/>
                    <measurement group_id="O12" value="NA">Insufficient data points for calculation</measurement>
                    <measurement group_id="O13" value="NA">Insufficient data points for calculation</measurement>
                    <measurement group_id="O14" value="NA">Insufficient data points for calculation</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>OZ439 Cmax</title>
        <description>Maximum observed plasma drug concentration (Cmax).</description>
        <time_frame>Samples collected from Pre-dose up to 96h post dose</time_frame>
        <population>Pharmacokinetics Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part A - 50 mg Single Dose</title>
            <description>OZ439 Single doses of 50mg (capsules)
OZ439 50mg API capsules</description>
          </group>
          <group group_id="O2">
            <title>Part A - 100mg Single Dose</title>
            <description>OZ439 Single doses of 100mg (capsules)
OZ439 100mg API capsules: OZ439 100mg (2x50mg API capsules)</description>
          </group>
          <group group_id="O3">
            <title>Part A - 200mg Single Dose</title>
            <description>OZ439 Single doses of 200mg (capsules)
OZ439 200mg API capsules</description>
          </group>
          <group group_id="O4">
            <title>Part A - 400mg Single Dose</title>
            <description>OZ439 Single doses of 400mg (capsules)
OZ439 400mg API capsules: OZ439 400mg (2x200mg API capsules)</description>
          </group>
          <group group_id="O5">
            <title>Part A - 400mg AD Single Dose</title>
            <description>OZ439 Single doses of 400mg (aqueous dispersion)
OZ439 400mg aqueous dispersion</description>
          </group>
          <group group_id="O6">
            <title>Part A - 800mg Single Dose</title>
            <description>OZ439 Single doses of 800mg (capsules)
OZ439 800mg API capsules: OZ439 800mg (4x200 API capsules)</description>
          </group>
          <group group_id="O7">
            <title>Part A - 800mg AD Single Dose</title>
            <description>OZ439 Single doses of 800mg (aqueous dispersion)
OZ439 800mg aqueous dispersion</description>
          </group>
          <group group_id="O8">
            <title>Part A - 1200mg Single Dose</title>
            <description>OZ439 Single doses of 1200mg (capsules)
OZ439 1200mg API capsules: OZ439 1200mg (6x200mg API capsules)</description>
          </group>
          <group group_id="O9">
            <title>Part A - 1600mg AD Single Dose</title>
            <description>OZ439 Single doses of 800mg (aqueous dispersion)
OZ439 1600mg aqueous dispersion</description>
          </group>
          <group group_id="O10">
            <title>Part B - 800mg AD Single Dose Fed</title>
            <description>Single dose of OZ439 800mg aqueous dispersion administered under fed conditions
OZ439 800mg aqueous dispersion</description>
          </group>
          <group group_id="O11">
            <title>Part B - 800mg AD Single Dose Fast</title>
            <description>Single dose of OZ439 800mg aqueous dispersion administered under fast conditions
OZ439 800mg aqueous dispersion</description>
          </group>
          <group group_id="O12">
            <title>Part C - 200mg AD Multiple Dose</title>
            <description>200mg aqueous solution OZ439 or placebo once daily for 3 days fasted
OZ439 200mg aqueous dispersion</description>
          </group>
          <group group_id="O13">
            <title>Part C - 400mg AD Multiple Dose</title>
            <description>400mg aqueous solution OZ439 or placebo once daily for 3 days fasted
OZ439 400mg aqueous dispersion</description>
          </group>
          <group group_id="O14">
            <title>Part C - 800mg AD Multiple Dose</title>
            <description>800mg aqueous solution OZ439 or placebo once daily for 3 days fasted
OZ439 800mg aqueous dispersion</description>
          </group>
        </group_list>
        <measure>
          <title>OZ439 Cmax</title>
          <description>Maximum observed plasma drug concentration (Cmax).</description>
          <population>Pharmacokinetics Population</population>
          <units>ng/ml</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="12"/>
                <count group_id="O11" value="12"/>
                <count group_id="O12" value="6"/>
                <count group_id="O13" value="6"/>
                <count group_id="O14" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.4" spread="84.7"/>
                    <measurement group_id="O2" value="34.2" spread="173.5"/>
                    <measurement group_id="O3" value="102" spread="82.9"/>
                    <measurement group_id="O4" value="135" spread="164.9"/>
                    <measurement group_id="O5" value="566" spread="53.9"/>
                    <measurement group_id="O6" value="315" spread="121.8"/>
                    <measurement group_id="O7" value="917" spread="35.6"/>
                    <measurement group_id="O8" value="701" spread="154.7"/>
                    <measurement group_id="O9" value="1340" spread="44.5"/>
                    <measurement group_id="O10" value="2220" spread="52.6"/>
                    <measurement group_id="O11" value="730" spread="61.1"/>
                    <measurement group_id="O12" value="342" spread="52.5"/>
                    <measurement group_id="O13" value="764" spread="46.6"/>
                    <measurement group_id="O14" value="1390" spread="51.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>OZ439 Tmax</title>
        <description>Time to maximum observed plasma drug concentration of OZ439</description>
        <time_frame>Samples collected from Pre-dose up to 96h post dose</time_frame>
        <population>Pharmacokinetics Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part A - 50 mg Single Dose</title>
            <description>OZ439 Single doses of 50mg (capsules)
OZ439 50mg API capsules</description>
          </group>
          <group group_id="O2">
            <title>Part A - 100mg Single Dose</title>
            <description>OZ439 Single doses of 100mg (capsules)
OZ439 100mg API capsules: OZ439 100mg (2x50mg API capsules)</description>
          </group>
          <group group_id="O3">
            <title>Part A - 200mg Single Dose</title>
            <description>OZ439 Single doses of 200mg (capsules)
OZ439 200mg API capsules</description>
          </group>
          <group group_id="O4">
            <title>Part A - 400mg Single Dose</title>
            <description>OZ439 Single doses of 400mg (capsules)
OZ439 400mg API capsules: OZ439 400mg (2x200mg API capsules)</description>
          </group>
          <group group_id="O5">
            <title>Part A - 400mg AD Single Dose</title>
            <description>OZ439 Single doses of 400mg (aqueous dispersion)
OZ439 400mg aqueous dispersion</description>
          </group>
          <group group_id="O6">
            <title>Part A - 800mg Single Dose</title>
            <description>OZ439 Single doses of 800mg (capsules)
OZ439 800mg API capsules: OZ439 800mg (4x200 API capsules)</description>
          </group>
          <group group_id="O7">
            <title>Part A - 800mg AD Single Dose</title>
            <description>OZ439 Single doses of 800mg (aqueous dispersion)
OZ439 800mg aqueous dispersion</description>
          </group>
          <group group_id="O8">
            <title>Part A - 1200mg Single Dose</title>
            <description>OZ439 Single doses of 1200mg (capsules)
OZ439 1200mg API capsules: OZ439 1200mg (6x200mg API capsules)</description>
          </group>
          <group group_id="O9">
            <title>Part A - 1600mg AD Single Dose</title>
            <description>OZ439 Single doses of 800mg (aqueous dispersion)
OZ439 1600mg aqueous dispersion</description>
          </group>
          <group group_id="O10">
            <title>Part B - 800mg AD Single Dose Fed</title>
            <description>Single dose of OZ439 800mg aqueous dispersion administered under fed conditions
OZ439 800mg aqueous dispersion</description>
          </group>
          <group group_id="O11">
            <title>Part B - 800mg AD Single Dose Fast</title>
            <description>Single dose of OZ439 800mg aqueous dispersion administered under fast conditions
OZ439 800mg aqueous dispersion</description>
          </group>
          <group group_id="O12">
            <title>Part C - 200mg AD Multiple Dose</title>
            <description>200mg aqueous solution OZ439 or placebo once daily for 3 days fasted
OZ439 200mg aqueous dispersion</description>
          </group>
          <group group_id="O13">
            <title>Part C - 400mg AD Multiple Dose</title>
            <description>400mg aqueous solution OZ439 or placebo once daily for 3 days fasted
OZ439 400mg aqueous dispersion</description>
          </group>
          <group group_id="O14">
            <title>Part C - 800mg AD Multiple Dose</title>
            <description>800mg aqueous solution OZ439 or placebo once daily for 3 days fasted
OZ439 800mg aqueous dispersion</description>
          </group>
        </group_list>
        <measure>
          <title>OZ439 Tmax</title>
          <description>Time to maximum observed plasma drug concentration of OZ439</description>
          <population>Pharmacokinetics Population</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="12"/>
                <count group_id="O11" value="12"/>
                <count group_id="O12" value="6"/>
                <count group_id="O13" value="6"/>
                <count group_id="O14" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="2" upper_limit="6"/>
                    <measurement group_id="O2" value="5" lower_limit="3" upper_limit="12"/>
                    <measurement group_id="O3" value="3.5" lower_limit="3" upper_limit="6"/>
                    <measurement group_id="O4" value="3" lower_limit="2" upper_limit="6"/>
                    <measurement group_id="O5" value="3" lower_limit="2" upper_limit="4"/>
                    <measurement group_id="O6" value="3" lower_limit="2" upper_limit="4"/>
                    <measurement group_id="O7" value="3" lower_limit="3" upper_limit="6"/>
                    <measurement group_id="O8" value="3" lower_limit="2" upper_limit="6"/>
                    <measurement group_id="O9" value="5" lower_limit="2" upper_limit="6"/>
                    <measurement group_id="O10" value="5" lower_limit="2" upper_limit="7"/>
                    <measurement group_id="O11" value="3" lower_limit="2" upper_limit="5"/>
                    <measurement group_id="O12" value="3" lower_limit="2" upper_limit="5"/>
                    <measurement group_id="O13" value="3" lower_limit="2" upper_limit="5"/>
                    <measurement group_id="O14" value="3" lower_limit="2" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>OZ439 t1/2</title>
        <description>Apparent terminal half-life (t1/2)</description>
        <time_frame>Samples collected from Pre-dose up to 96h post dose</time_frame>
        <population>Pharmacokinetics Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part A - 50 mg Single Dose</title>
            <description>OZ439 Single doses of 50mg (capsules)
OZ439 50mg API capsules</description>
          </group>
          <group group_id="O2">
            <title>Part A - 100mg Single Dose</title>
            <description>OZ439 Single doses of 100mg (capsules)
OZ439 100mg API capsules: OZ439 100mg (2x50mg API capsules)</description>
          </group>
          <group group_id="O3">
            <title>Part A - 200mg Single Dose</title>
            <description>OZ439 Single doses of 200mg (capsules)
OZ439 200mg API capsules</description>
          </group>
          <group group_id="O4">
            <title>Part A - 400mg Single Dose</title>
            <description>OZ439 Single doses of 400mg (capsules)
OZ439 400mg API capsules: OZ439 400mg (2x200mg API capsules)</description>
          </group>
          <group group_id="O5">
            <title>Part A - 400mg AD Single Dose</title>
            <description>OZ439 Single doses of 400mg (aqueous dispersion)
OZ439 400mg aqueous dispersion</description>
          </group>
          <group group_id="O6">
            <title>Part A - 800mg Single Dose</title>
            <description>OZ439 Single doses of 800mg (capsules)
OZ439 800mg API capsules: OZ439 800mg (4x200 API capsules)</description>
          </group>
          <group group_id="O7">
            <title>Part A - 800mg AD Single Dose</title>
            <description>OZ439 Single doses of 800mg (aqueous dispersion)
OZ439 800mg aqueous dispersion</description>
          </group>
          <group group_id="O8">
            <title>Part A - 1200mg Single Dose</title>
            <description>OZ439 Single doses of 1200mg (capsules)
OZ439 1200mg API capsules: OZ439 1200mg (6x200mg API capsules)</description>
          </group>
          <group group_id="O9">
            <title>Part A - 1600mg AD Single Dose</title>
            <description>OZ439 Single doses of 800mg (aqueous dispersion)
OZ439 1600mg aqueous dispersion</description>
          </group>
          <group group_id="O10">
            <title>Part B - 800mg AD Single Dose Fed</title>
            <description>Single dose of OZ439 800mg aqueous dispersion administered under fed conditions
OZ439 800mg aqueous dispersion</description>
          </group>
          <group group_id="O11">
            <title>Part B - 800mg AD Single Dose Fast</title>
            <description>Single dose of OZ439 800mg aqueous dispersion administered under fast conditions
OZ439 800mg aqueous dispersion</description>
          </group>
          <group group_id="O12">
            <title>Part C - 200mg AD Multiple Dose</title>
            <description>200mg aqueous solution OZ439 or placebo once daily for 3 days fasted
OZ439 200mg aqueous dispersion</description>
          </group>
          <group group_id="O13">
            <title>Part C - 400mg AD Multiple Dose</title>
            <description>400mg aqueous solution OZ439 or placebo once daily for 3 days fasted
OZ439 400mg aqueous dispersion</description>
          </group>
          <group group_id="O14">
            <title>Part C - 800mg AD Multiple Dose</title>
            <description>800mg aqueous solution OZ439 or placebo once daily for 3 days fasted
OZ439 800mg aqueous dispersion</description>
          </group>
        </group_list>
        <measure>
          <title>OZ439 t1/2</title>
          <description>Apparent terminal half-life (t1/2)</description>
          <population>Pharmacokinetics Population</population>
          <units>hours</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="12"/>
                <count group_id="O11" value="12"/>
                <count group_id="O12" value="6"/>
                <count group_id="O13" value="6"/>
                <count group_id="O14" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Below level of detection</measurement>
                    <measurement group_id="O2" value="NA">Below level of detection</measurement>
                    <measurement group_id="O3" value="NA">Below level of detection</measurement>
                    <measurement group_id="O4" value="NA">Below level of detection</measurement>
                    <measurement group_id="O5" value="31.2" spread="33.5"/>
                    <measurement group_id="O6" value="27.9" spread="24.1"/>
                    <measurement group_id="O7" value="25.2" spread="25.8"/>
                    <measurement group_id="O8" value="31.6" spread="46.9"/>
                    <measurement group_id="O9" value="30.7" spread="41.9"/>
                    <measurement group_id="O10" value="31.7" spread="30.1"/>
                    <measurement group_id="O11" value="38.8" spread="50.2"/>
                    <measurement group_id="O12" value="41.7" spread="18.2"/>
                    <measurement group_id="O13" value="40.8" spread="31.4"/>
                    <measurement group_id="O14" value="37.8" spread="28.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>OZ439 Rac</title>
        <description>Accumulation index is the ratio of drug exposure observed during a dosing interval at steady-state divided by drug exposure after a single first dose, as described by the following equations:
Accumulation index (Rac) = AUC0-(Day 3)/ AUC0-(Day 1)</description>
        <time_frame>Samples collected from Pre-dose up to 96h post dose</time_frame>
        <population>Pharmacokinetics Population received multiple dosing only. This PK parameter is not applicable in a single dose setting.</population>
        <group_list>
          <group group_id="O1">
            <title>Part C - 200mg AD Multiple Dose</title>
            <description>200mg aqueous solution OZ439 or placebo once daily for 3 days fasted
OZ439 200mg aqueous dispersion</description>
          </group>
          <group group_id="O2">
            <title>Part C - 400mg AD Multiple Dose</title>
            <description>400mg aqueous solution OZ439 or placebo once daily for 3 days fasted
OZ439 400mg aqueous dispersion</description>
          </group>
          <group group_id="O3">
            <title>Part C - 800mg AD Multiple Dose</title>
            <description>800mg aqueous solution OZ439 or placebo once daily for 3 days fasted
OZ439 800mg aqueous dispersion</description>
          </group>
        </group_list>
        <measure>
          <title>OZ439 Rac</title>
          <description>Accumulation index is the ratio of drug exposure observed during a dosing interval at steady-state divided by drug exposure after a single first dose, as described by the following equations:
Accumulation index (Rac) = AUC0-(Day 3)/ AUC0-(Day 1)</description>
          <population>Pharmacokinetics Population received multiple dosing only. This PK parameter is not applicable in a single dose setting.</population>
          <units>ratio</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.16" spread="18.7"/>
                    <measurement group_id="O2" value="1.76" spread="29.9"/>
                    <measurement group_id="O3" value="1.43" spread="26.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event monitoring throughout the admission period.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Part A - 50 mg Single Dose</title>
          <description>OZ439 Single doses of 50mg (capsules)
OZ439 50mg API capsules</description>
        </group>
        <group group_id="E2">
          <title>Part A - 100mg Single Dose</title>
          <description>OZ439 Single doses of 100mg (capsules)
OZ439 100mg API capsules: OZ439 100mg (2x50mg API capsules)</description>
        </group>
        <group group_id="E3">
          <title>Part A - 200mg Single Dose</title>
          <description>OZ439 Single doses of 200mg (capsules)
OZ439 200mg API capsules</description>
        </group>
        <group group_id="E4">
          <title>Part A - 400mg Single Dose</title>
          <description>OZ439 Single doses of 400mg (capsules)
OZ439 400mg API capsules: OZ439 400mg (2x200mg API capsules)</description>
        </group>
        <group group_id="E5">
          <title>Part A - 400mg Single Dose + Food</title>
          <description>OZ439 Single doses of 400mg (capsules) administered with food.
OZ439 400mg API capsules: OZ439 400mg (2x200mg API capsules)</description>
        </group>
        <group group_id="E6">
          <title>Part A - 400mg AD Single Dose</title>
          <description>OZ439 Single doses of 400mg (aqueous dispersion)
OZ439 400mg aqueous dispersion</description>
        </group>
        <group group_id="E7">
          <title>Part A - 800mg Single Dose</title>
          <description>OZ439 Single doses of 800mg (capsules)
OZ439 800mg API capsules: OZ439 800mg (4x200 API capsules)</description>
        </group>
        <group group_id="E8">
          <title>Part A - 800mg AD Single Dose</title>
          <description>OZ439 Single doses of 800mg (aqueous dispersion)
OZ439 800mg aqueous dispersion</description>
        </group>
        <group group_id="E9">
          <title>Part A - 1200mg Single Dose</title>
          <description>OZ439 Single doses of 1200mg (capsules)
OZ439 1200mg API capsules: OZ439 1200mg (6x200mg API capsules)</description>
        </group>
        <group group_id="E10">
          <title>Part A - 1600mg AD Single Dose</title>
          <description>OZ439 Single doses of 800mg (aqueous dispersion)
OZ439 1600mg aqueous dispersion</description>
        </group>
        <group group_id="E11">
          <title>Part A - Placebo</title>
          <description>Placebo control for Single rising Part A
Placebo</description>
        </group>
        <group group_id="E12">
          <title>Part B - 800mg AD Single Dose Fed</title>
          <description>Single dose of OZ439 800mg aqueous dispersion administered under fed conditions
OZ439 800mg aqueous dispersion</description>
        </group>
        <group group_id="E13">
          <title>Part B - 800mg AD Single Dose Fast</title>
          <description>Single dose of OZ439 800mg aqueous dispersion administered under fast conditions
OZ439 800mg aqueous dispersion</description>
        </group>
        <group group_id="E14">
          <title>Part C - 200mg AD Multiple Dose</title>
          <description>200mg aqueous solution OZ439 or placebo once daily for 3 days fasted
OZ439 200mg aqueous dispersion</description>
        </group>
        <group group_id="E15">
          <title>Part C - 400mg AD Multiple Dose</title>
          <description>400mg aqueous solution OZ439 or placebo once daily for 3 days fasted
OZ439 400mg aqueous dispersion</description>
        </group>
        <group group_id="E16">
          <title>Part C - 800mg AD Multiple Dose</title>
          <description>800mg aqueous solution OZ439 or placebo once daily for 3 days fasted
OZ439 800mg aqueous dispersion</description>
        </group>
        <group group_id="E17">
          <title>Part C - Placebo</title>
          <description>Placebo control for Multiple rising Part C
Placebo</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="4" subjects_at_risk="17"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E13" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E14" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrioventricular Block</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Disconfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="3" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Hypermotility</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="3" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Oropharyngeal Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Throat Irritation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Oral Herpes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood Creatine Phosphokinase Increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Blood Pressure Increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Flank Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E12" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E14" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Pelvic Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nasal Congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Throat Irritation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Syncope Vasovagal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Joerg Moehrle</name_or_title>
      <organization>Medicines for Malaria Venture</organization>
      <phone>+41 22 555 0330</phone>
      <email>moehrlej@mmv.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

